IDEC-152 has the potential to decrease the body’s response to allergens, thereby affecting diseases related to asthma and allergic disorders. IDEC’s monoclonal antibody binds to the CD23 receptor. By binding to this receptor, IDEC-152 may favorably influence asthma through its selective regulation of IgE production and its inhibition of other inflammatory pathways.
Clinical Trial Update
In March 2001 at the 57th Annual Meeting of the American Academy of Allergy, Asthma and Immunology in New Orleans. IDEC announced results from a single-dose, placebo-controlled, dose-escalating Phase I trial of its investigational agent IDEC-152, a PRIMATIZED® anti-CD23 monoclonal antibody in patients with allergic asthma.
In the study 30 patients received either a single intravenous infusion of one of several dosage levels of IDEC-152 or placebo. Substantial reductions in IgE levels were noted in patients treated with IDEC-152, along with an encouraging safety profile. In this placebo-controlled study, rates of adverse events were similar between IDEC-152 treated patients and placebo-treated patients. In addition, a substantial and durable reduction of Immunoglobulin E (IgE) levels was noted in a dose-dependent fashion in IDEC-152 treatment groups. This combination of safety and reduction in IgE levels after only a single dose is promising and lays a strong foundation for further multiple-dose studies.
As an indication, allergic asthma would benefit from additional therapeutic options. Safety is critical in an indication with a large number of young and, otherwise, healthy patients. For this reason the safety profile and the prolonged reduction in IgE levels after only a single dose noted in this study are encouraging.
IDEC expects to launch a Phase I/II clinical trial in the first quarter of 2002.
Ex-US Marketing Rights
Seikagaku Corporation has licensed the commercial rights of IDEC-152 in Europe and Asia. IDEC retains exclusive rights outside of Europe and Asia.